ImmunoTherapyNews.net

Cancer immunotherapy

Xagena Mappa
Medical Meeting
Onco News
Farmaexplorer.it

Search results for "Immune checkpoint inhibitor"

Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. Researchers have assessed the activity of Nivolumab ( Opdivo ), a fully human IgG4 PD-1 ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activ ...


Nivolumab ( Opdivo ) is a programmed death-1 ( PD-1 ) immune checkpoint inhibitor which has shown durable tumor responses in multiple cancer types and prolongs overall survival in patients with melano ...


Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small cell lung cancer ( NSCLC ), with a five-year survival rate of ...


Programmed cell death protein ligand-1 ( PD-L1 ) inhibitors are novel anti-cancer therapies but are associated with potentially therapy limiting immune-related adverse effects ( IRAEs ). The purpos ...


Cancer immunotherapy with checkpoint inhibitors ( CPIs ) is associated with frequent immune-related adverse events ( irAEs ) and is often not recommended for patients with concomitant autoimmune disea ...


The purpose of the study was to describe the prevalence, clinical presentation, and management of rheumatic immune‐related adverse effects ( Rh‐irAEs ) from immune checkpoint inhibitor ( ICI ) therapy ...


Hyperprogression, a paradoxical boost in tumor growth, was described in a subset of patients treated with immune checkpoint inhibitors ( ICI ). Neither clinicopathologic features nor biological mech ...


A subset of patients treated with immune checkpoint inhibitors experience an accelerated tumor growth rate ( TGR ) in comparison with pretreatment kinetics; this is known as hyperprogression. A stud ...